Annexin Pharmaceuticals AB (publ) (ANNX.ST)
SEK 0.43
(-1.61%)
SEK 0.43
(-1.61%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.26 SEK | -52.94% |
| 2022 | -0.17 SEK | 56.41% |
| 2021 | -0.39 SEK | 0.0% |
| 2020 | -0.39 SEK | 31.58% |
| 2019 | -0.57 SEK | 58.39% |
| 2018 | -1.37 SEK | 62.97% |
| 2017 | -3.70 SEK | -230.36% |
| 2016 | -1.12 SEK | 23.81% |
| 2015 | -1.47 SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.04 SEK | 14.52% |
| 2024 Q2 | -0.04 SEK | -11.42% |
| 2024 Q3 | -0.02 SEK | 48.75% |
| 2023 Q3 | -0.04 SEK | -26.48% |
| 2023 Q2 | -0.03 SEK | 15.53% |
| 2023 FY | - SEK | -47.06% |
| 2023 Q1 | -0.04 SEK | 4.28% |
| 2023 Q4 | -0.04 SEK | -3.45% |
| 2022 Q2 | -0.08 SEK | -20.78% |
| 2022 Q1 | -0.07 SEK | 42.67% |
| 2022 Q4 | -0.04 SEK | 36.98% |
| 2022 Q3 | -0.06 SEK | 24.19% |
| 2022 FY | - SEK | 56.41% |
| 2021 Q1 | -0.27 SEK | -28.57% |
| 2021 Q2 | -0.12 SEK | 55.56% |
| 2021 Q4 | -0.12 SEK | -20.0% |
| 2021 FY | - SEK | 0.0% |
| 2021 Q3 | -0.10 SEK | 16.67% |
| 2020 Q3 | -0.10 SEK | 33.33% |
| 2020 Q4 | -0.21 SEK | -110.0% |
| 2020 Q1 | -0.14 SEK | 58.82% |
| 2020 FY | - SEK | 31.58% |
| 2020 Q2 | -0.15 SEK | -7.14% |
| 2019 Q3 | -0.33 SEK | -10.0% |
| 2019 FY | - SEK | 58.39% |
| 2019 Q4 | -0.34 SEK | -3.03% |
| 2019 Q2 | -0.30 SEK | -66.67% |
| 2019 Q1 | -0.18 SEK | 25.0% |
| 2018 Q2 | -0.56 SEK | 37.78% |
| 2018 Q1 | -0.90 SEK | 5.26% |
| 2018 Q3 | -0.16 SEK | 71.43% |
| 2018 Q4 | -0.24 SEK | -50.0% |
| 2018 FY | - SEK | 62.97% |
| 2017 Q1 | -2.17 SEK | -1.4% |
| 2017 FY | - SEK | -230.36% |
| 2017 Q2 | -1.01 SEK | 53.46% |
| 2017 Q3 | -0.38 SEK | 62.38% |
| 2017 Q4 | -0.95 SEK | -150.0% |
| 2016 Q2 | -8.12 SEK | -39.76% |
| 2016 Q1 | -5.81 SEK | 0.0% |
| 2016 FY | - SEK | 23.81% |
| 2016 Q4 | -2.14 SEK | 25.44% |
| 2016 Q3 | -2.87 SEK | 64.66% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |